TMCnet News
Schistosomiasis Pipeline Review, H2 2016 Featuring Kancera, LondonPharma, Merck & Salvensis - Research and MarketsResearch and Markets has announced the addition of the "Schistosomiasis - Pipeline Review, H2 2016" report to their offering. 'Schistosomiasis - Pipeline Review, H2 2016'; Schistosomiasis pipeline therapeutics constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities Institutes. Schistosomiasis is a type of infection caused by parasites that live in fresh water, such as rivers or lakes. Symptoms include a high temperature, headache, cough, a dark red, blotchy, raised skin rash, pain in the abdomen and joint and muscle pain. 'Schistosomiasis - Pipeline Review, H2 2016' outlays comprehensive information on the therapeutics under development for Schistosomiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule ype; that are being developed by Companies / Universities. It also reviews of key players involved in therapeutic development for Schistosomiasis and features dormant and discontinued projects. Currently, The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively. Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/7c88z2/schistosomiasis
View source version on businesswire.com: http://www.businesswire.com/news/home/20161028005674/en/ |
